Biomea Fusion stock soars on early-stage diabetes data

Redwood City, CA-based Biomea Fusion saw about a 50% increase in its stock today after revealing early data for its covalent menin inhibitor, BMF-219, for the treatment of type 2 diabetes.

Data from two cohorts enrolled in the Phase II portion of its ongoing Phase I/II clinical study showed potential…